|
2011
2010
2009
|
Acquisition of Q-Med, a Swedish company specialized in aesthetic & corrective solutions.
Emervel (dermal filler range) launch in Europe and Latin America.
Launch of Cetaphil Restoraderm.
Plant extensions in France and Canada.
Differin Lotion 0.1% (acne) launch in the United States.
Galderma hits the 1 billion mark in sales.
Launch of Azzalure (glabellar lines) and Oracea in Europe.
Vectical (psoriasis) launch in the United-States. Oracea
|
| 2008 |
Epiduo (acne) launch.
Acquisition of CollaGenex Pharmaceuticals and its product Oracea (rosacea).
Launch of Differin 0.1% in Japan. Differin |
| 2007 |
Licensing agreements for a botulinum toxin type A and Pliaglis (topical anesthetic).
Differin 0.3% launch. Pliaglis |
| 2006 |
Clobex Spray launch in the US.
Opening of the new R&D center in Sophia Antipolis, France. |
| 2005 |
Metrogel 1% (rosacea) launch in the United-States.
For the first time, Galderma ranks Number One in D class in its markets
(source: IMS Health, IMS dataview - D class - MAT Q3 2005 - 33 countries). |
| 2004 |
Opening of a new production site in Hortolandia, Brazil.
Clobex Shampoo launch in the United-States and acquisition of Tri-Luma. |
| 2003 |
Launch of Metvix in Germany and the UK and Clobex Lotion (inflammatory skin conditions) in the US. |
| 2002 |
Licensing agreements for Tri-Luma (melasma or mask of pregnancy) and Pekiron (Loceryl Cream) in Japan.
First FDA approvals for pharmaceutical production in Montreal. |
| 2001 |
Licensing agreement for Metvix (precancerous skin lesions and skin cancer treatment).
Launch of Clindagel (anti-acne). |
| 2000 |
The Montreal production unit comes on stream.
Launch of Silkis (psoriasis) and acquisition of Capex Shampoo (seborrheic dermatitis). |
| 1999 |
Acquisition of Loceryl (fungal nail infections), developed by Laboratoires Roche, together with the Scandinavian dermatology portfolio developed by Nycomed. |
| 1998 |
Inauguration of a new R&D facility in Princeton, New Jersey, USA.
Acquisition in Brazil of Darrow’s dermatology portfolio. |
| 1997 |
Acquisition of Basotherm, a subsidiary of Boehringer. |
| 1996 |
Acquisition of a plant belonging to Wyeth-Ayerts in Montreal, Canada, to develop a state-of-the-art manufacturing plant. |
| 1995 |
Launch of anti-acne treatment Differin, Galderma’s first home-grown dermatology product. |
| 1994 |
Galderma inaugurates its wholly-owned production plant in Alby-sur-Chéran, near Annecy in the French Alps. |
| 1993 |
Acquisition of MetroGel / Rozex to include rosacea treatments in the product portfolio. |
| 1989 |
Global organization implemented and new affiliates opened in Canada, Germany, Spain and the United Kingdom. |
| 1988 |
Galderma progressively takes over Alcon’s dermatology business, allowing it to focus exclusively on ophthalmology. |
| 1986 |
Galderma’s first affiliate opens for business in France, followed by a second in Italy. The International Dermatology Research Center focuses its efforts on prescription dermatology products. |
| 1981 |
Nestlé and L'Oréal form a joint venture to become the world’s leading dermatology player. Galderma is born. |
| 1979 |
L'Oréal creates its International Dermatology Research Center (CIRD) in Sophia-Antipolis, France, specializing in fundamental research into skin physiology. |
| 1977 |
Nestlé acquires Alcon to strengthen its presence in the North American market. |
| 1972 |
Acquisition of Owen by ophthalmology specialist Alcon, headquartered in Fort Worth, Texas. |
| 1961 |
Creation of the Owen dermatology company in Dallas, Texas, USA.
|